Autoimmune Treatment – Aarkstore Enterprise

Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.

The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.

The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.

The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.

The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014.
Scope of the Report

The report provides market overviews and forecasts as well as market drivers and restraints for the global autoimmune treatment market. In addition, it profiles the top forty market players and their respective autoimmune products. The report identifies and analyzes the market according to application markets for both systemic and localized autoimmune diseases, product markets, services market and technologies market.

Autoimmune Treatment – Applications
• Systemic autoimmune diseases – rheumatoid arthritis, psoriasis, lupus, and other systemic autoimmune diseases.
• Localized autoimmune diseases – multiple sclerosis, inflammatory bowel disease, diabetes, thyroid, and other localized autoimmune diseases.

Autoimmune Treatment – Products
Drugs, diagnostic equipment, therapeutic and monitoring equipment, and other products.

Autoimmune Treatment – Services
Consultation & Diagnosis, Therapy & Monitoring, Drug Development, and other services.

Autoimmune Treatment – Technologies
DMARD (disease-modifying anti-rheumatic drugs) and biologic DMARD therapy, Bridge therapy, Topical therapy, Phototherapy, Helminthic therapy, Fecal bacteriotherapy, Haematopoietic stem-cell transplantation, Recombinant technology

What makes our reports unique?

• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 4.

• Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 200 patents and minimum 40 micro markets, which are collectively exhaustive and mutually exclusive.

• No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – North America, Europe, Asia Pacific and ROW.

• We provide 10% customization- normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

• 15 pages of high level analysis including benchmarking strategies, best practices (five level of products) and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

Key questions answered

• Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Autoimmune-Treatment-2009-2014–27513.html

The Asian Cardiovascular Market Outlook to 2014: Regional and therapeutic analysis, pipeline impact and growth opportunities – Aarkstore Enterprise

The Asian cardiovascular market demonstrated robust sales, unlike the global market which has begun to slow down due to patent expiries of class leading products and strong generic competition. The emerging ten Asian markets analyzed in this report is a mixture of developed nations like South Korea, Taiwan, Hong Kong, Singapore and Malaysia, and developing markets such as China, India, Thailand, Philippines and Indonesia. Although these markets have lower healthcare expenditure per head compared to the US and EU, the Asian markets are regarded as the potential growth markets of the health services industry and consequently the pharmaceutical sector. The market is also being driven by the shift of focus from primary care to specialty care. In comparison to the western markets drug patent expiries minimally affect proprietary brand growth dynamics in Asia. Regional customization of brand prices and aggressive marketing strategies have positioned branded drugs in direct competition with generic brands.

Table of Contents :
Executive Summary
Patient potential
Regional healthcare and licensing trends
Regional market analysis
Key players in the Asian cardiovascular market
Chapter 1 Scope and methodology
Scope
Key CV sub-therapy areas covered in this report
Methodology
Chapter 2 Patient potential
Summary
Introduction
Disease description
Defining patient potential
Limitations of cardiovascular epidemiology data
Cardiovascular risk factors
Hypertension
Dyslipidemia
Diabetes
Cardiovascular disease
Acute thrombotic events
Acute coronary syndrome
Venous thromboembolism
Stroke
Chapter 3 Regional healthcare and licensing trends
Summary
Introduction
Regional healthcare expenditure
Healthcare financing
The external environment
Licensing analysis
Chapter 4 Regional market analysis
Summary
Introduction
Leading cardiovascular therapy areas
Leading Asian cardiovascular markets
Leading cardiovascular brands
Antihypertensives
Introduction
Leading antihypertensive brands
Regional dynamics
Market analysis by drug class
Calcium channel blockers: driven by replacability
Angiotensin receptor blockers: driven by efficacy
ACE inhibitors: downplayed by side effects
Beta-blockers: driven by pricing
Diuretics: outdated and stabilizing
Antihypertensives sales forecasts
Anti-dyslipidemics
Introduction
Leading anti-dyslipidemic brands
Regional dynamics
Market analysis by drug class
Statins: irreplacable dominance
Fibrates: outdated
Other anti-dyslipidemics
Anti-dyslipidemics sales forecast
Cardiac therapies
Introduction
Leading cardiac therapy brands
Market analysis by drug class
Nitrates/nitrites: driven by pricing
Anti-arrhythmics: overcome by nitrates
Others
Cardiac therapies sales forecasts
Anti-thrombotics
Introduction
Leading anti-thrombotic brands
Regional dynamics
Market analysis by drug class
Heparins/low molecular weight heparins: overshadowed by antiplatelets
Vitamin K antagonists: outdated
Oral anti-platelets: preventive advantage drives sales
Fibrinolytics: driven by emergency care demands
Anti-thrombotic sales forecasts
Chapter 5 Key players in the Asian cardiovascular market
Summary
Introduction
Key events and trends
Global CV research affected by ‘Lipitorphobia’; diffused impact on Asia
From a single wheeled to multi-wheeled structure: reducing dependence on the CV sector, target Asia
HDL mimetics will minimally drive the Asian market
Asian market shares
Pfizer: contemplating a paradigm shift
Country focus
Therapy focus
Key brands
Pipeline
Apixaban
Cardiovascular portfolio sales forecasts
Sanofi-Aventis
Country focus
Therapy focus
Key brands
Pipeline
Multaq
Cardiovascular portfolio sales forecasts
AstraZeneca
Country focus
Therapy focus
Key brands
Pipeline
Ticagrelor
Cardiovascular portfolio sales forecasts
Novartis
Country focus
Therapy focus
Key brands
Pipeline
Tekturna
Cardiovascular portfolio sales forecasts
Merck & Co
Country focus
Therapy focus
Key brands
Pipeline
Anacetrapib
Cardiovascular portfolio sales forecasts
Bayer
Country focus
Therapy focus
Key brands
Pipeline: Xarelto to capture Lovenox market
Xarelto
Cardiovascular portfolio sales forecasts
GSK
Country focus
Therapy focus
Key brands
Pipeline
Letairis
Cardiovascular portfolio sales forecasts
Servier
Country focus
Therapy focus
Key brands
Pipeline
Cardiovascular portfolio sales forecasts
Roche
Country focus
Therapy focus
Key brands
Pipeline
Dalcetrapib
Cardiovascular portfolio sales forecasts
Boehringer Ingelheim
Country focus
Therapy focus
Key brands
Pipeline
Cardiovascular portfolio sales forecasts
Forecast rankings of the key players, 2014
Chapter 6 Appendix
IMS Data
C1 Cardiac therapy
C2 Antihypertensives
C3 Diuretics
C4 Cerebral and peripheral vasotherapeutics
C5 Antivaricosis/anti-haemorrhoidal preparations
C6 Other cardiovascular products
C7 Beta-blocking agents
C8 Calcium antagonists
C9 Agents acting on the renin-angiotensin system
C10 Lipid-regulating/anti-atheroma preparations
C11 Cardiovascular multitherapy combination products
B1 Anti-thrombotic agents
B2 Antifibrinolytics, antidotes to anti-coagulants, inhibitors, blood coagulation and haemostyptics
B3 Anti-anaemic preparations
B6 All other haematological agentsGlossary
Glossary
Index

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Asian-Cardiovascular-Market-Outlook-to-2014-Regional-and-therapeutic-analysis-pipeline-impact-and-growth-opportunities-13974.html

The Canadian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities – Aarkstore Enterprise

The Canadian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

This report provides comprehensive coverage of the Canadian market, incorporating an overview of the country, its socioeconomic status and the epidemiological scenario of major pathophysiological disorders. Furthermore, the report analyzes the scenario in Canada pertaining to pharmaceutical regulation, pricing and reimbursement. Finally, the report analyzes the marketed product portfolios, R&D pipelines and market share data of the leading pharmaceutical companies in Canada, and provides sales forecasts.

Table of Contents :

Pharmaceutical distribution
Independent pharmacy distributors (IPD)
Self-distributors
Retail and hospital pharmacies
Independent pharmacies
Pharmacy groups
Hospital pharmacies
Pharmaceutical sales and market analysis
Drug sales by province and territory
Licensing trends
Market analysis by therapeutic area
Market analysis by drug classes
Market analysis by leading brands
Market analysis by key players
Branded drug manufacturers
Pfizer Canada
Sales analysis by therapeutic area
Sales analysis of leading brands
J&J Canada

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Canadian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities-13976.html

The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities – Aarkstore Enterprise

The Scandinavian Pharma Market Outlook to 2013: Policy environment, market structure, pipeline analysis and growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated, with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality are the ideological basis of these welfare states, and a significant public commitment exists towards ensuring access to high quality health care for all citizens. Sweden and Denmark have been the two biggest pharma and biotech markets in Scandinavia, while regional players such as Novo Nordisk have laid the foundations for this industry in the region.

‘The Scandinavian Pharmaceutical Market Outlook to 2013’ is a report published explores the healthcare systems and policy environments of Denmark, Norway, Sweden and Finland. This report examines the region’s market potential by assessing historic epidemiological data, sales trends, competitive intelligence and clinical data across each major country. The growth drivers of the region are identified and forecasts for major prescription drugs and markets are provided for the period 2009-13. The competitive landscape of the Scandinavian market is also evaluated, with the region’s five leading companies being assessed based upon their marketed product portfolios and R&D pipelines in order to forecast their future competitive positions.

Key Findings

The Scandinavian pharma market recorded sales of $10.1bn in 2007, a 16% increase over 2006. Sweden had the largest market share (38%), followed by Finland (23%), Denmark (22%), and Norway (17%). These countries possess developed infrastructures, advanced technologies, R&D support and business friendly cultures. Pfizer led the Scandinavian market in 2007 with sales of $696m, a 6.3% increase over 2006.

Pfizer has a significant presence in all four Scandinavian markets and in the leading therapeutic areas of the region. Drugs for the treatment of CNS disorders are the largest product class in Scandinavia, with a market share of 20.7% in 2007. Cancer and cardiovascular diseases are the next largest therapeutic categories in the region.

Well-developed biotech and life sciences clusters across the Scandinavian region enable world-class research and provide pools of well-educated personnel and versatile facilities to support start-up companies.

Parallel trade has become a major concern for the profitability of Scandinavia-based Pharma companies in recent years. Factors driving this include lower prescription drug expenditures sought by payors and parallel traders’ strategies benefit from price differentials for drugs across different countries.

Use this report to…

• Compare the healthcare markets of key Scandinavian countries with this report’s macroeconomic analysis of infrastructure, per capita health expenditure and Pharma sales growth vs. GDP growth across Sweden, Finland, Denmark and Norway.

• Understand how healthcare policy environments vary across the region with this report’s examination of drug approval processes, pricing regulations and reimbursement policies in each major country.

• Identify which indications have the greatest potential to provide franchise growth with this report’s evaluation of major therapy/sub-therapy areas and leading brands, including forecast sales over the period 2009-2013.

• Measure the performances and prospects of leading companies in the Scandanavian area with this report’s strategic analysis of leading pharma corporations based on sales focus by drug class, currently marketed products and R&D pipeline portfolios.

Explore issues including…

The threat to EU health spending. Pharma activity in the Scandinavian market is focused around cost containment, but in recent years the consumption of generics and parallel imports has slowly increased. A new pricing regime linked to other European countries has also had a moderating effect on price levels in Scandinavian countries over recent years.

Higher licensing deal values. Competition for promising projects (particularly drugs that have established solid proof-of-concept data) has not only boosted the deal values overall, but also increased the quantity and average value of deals in the early stages of product development.

Parallel trade influencing pricing. The prevalence of parallel trade is having a significant impact upon state expenditure on drugs and consumer prices. In Sweden, parallel imports have been included as substitutable products in accordance with the generic substitution policy, giving significant boost to parallel imported products in the country.

Support for generic substitution of patented drugs. A report by the National Trade Estimate of the United States Trade Representative (USTR) made special mention of Finland, due to the country’s Pharma Pricing Board not always waiting for the expiry of the analogous process patent before taking action.Discover…

• What will be the major growth drivers in the Scandinavian pharma market over 2009-13?

• Which companies were the winners and losers in the Scandinavian pharma market in 2007?

• Which companies will become key players over 2009 -13?

• Which products will be affected by generic competitors over the period 2009-13?

• Which pipeline products will be the growth drivers of the future?

• Which therapy areas and indications have the highest market potential over 2009-13?

• How will the Scandinavian pharma market’s competitive landscape change by 2013?

 For more information, kindly visit :
http://www.aarkstore.com/reports/The-Scandinavian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities-13979.html

Drug and Device Combination – Aarkstore Enterprise

Drug-device combination is defined as the combination of drugs and medical devices that can be chemically or physically united or co-packaged as separate, cross labeled products. The commercialization cycle from R&D to product shows the immense potential of the bundled offering. Currently, the market has a potential of US$10.6 billion and has been experiencing a growth of 15% CAGR for the past two years. In the next five years, the market is expected to grow at a CAGR of 11.8%. A future view of the drug-device combination is that these products will make single component medical devices obsolete.

The drug-eluting stents (DES) market is the largest segment in the drug-device combination market. This is supported by the fact that cardiovascular applications constitute about 64% of the entire drug-device combination applications market. However, it is the relatively smaller market of antimicrobial catheter that offers the highest growth potential over the next five years in the overall market.

The DES market is further segmented into stent grafts, coronary stents and peripheral vascular stents. Though coronary stents has the highest market share, peripheral vascular stents is expected to have the highest growth rate till 2014. The fastest growing macro-market of antimicrobial catheter is segmented into micro-markets such as urological catheter, cardiovascular catheter, peripherally inserted central catheter, oximetry catheter, thermodilution catheter and wound drainage catheter. Closed loop glucose monitor and insulin pump is also expected to record a high growth rate for the period 2009 to 2014. The two major segments: steroid eluting electrodes and photodynamic therapy are estimated to see the slowest growth rate due to a slow development of new products in these markets.

The challenges crippling the growth of the market in the future are expected to be the issues involved in cross industry partnerships, jurisdiction issues, patient safety and interoperability issues.

The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.

There is an immense scope of collaboration between the drugs and medical devices companies in the areas of closed loop glucose monitor and insulin pump, bone graft substitutes and advanced wound care products market. However, the antibiotic bone cements and advanced wound care market is expected to face stiff competition in the next five years to come.

The incremental benefits of these combination products over the regular medical devices are increased efficiency, reduction in overall cost of treatment along with the rising awareness. The market holds significant opportunity for the early movers albeit with extensive research to develop new and improved products at competitive prices. Successful strategic alliances between companies from the drugs and medical devices areas assist them in taking advantage of the existing technologies by avoiding capital expenditure in R&D and take the drug-device combination market to new heights.
 

What makes our reports unique?

1. We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.

2. Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.

3. No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.

4. We provide 10% customization- normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.

5. 15 pages of high level analysis including benchmarking strategies, best practices and the market?s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

6. Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

1. Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?

2. What are market estimates and forecasts; which markets are doing well and which are not?

3. Where are the gaps and opportunities; what is driving the market?

4. Which are the key playing fields? Which are the winning edge imperatives?

5. How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For more information, visit us at:
http://www.aarkstore.com/reports/Drug-and-Device-Combination-2009-2014–16959.html

Alzheimer Disease Therapy Area Pipeline Report – Aarkstore Enterprise

Alzheimer Disease Therapy Area Pipeline Report contains detailed information on the alzheimer disease drug pipeline. This report provides insight into the pipeline status of alzheimer disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.

For more information, kindly visit :
http://www.aarkstore.com/reports/Alzheimer-Disease-Therapy-Area-Pipeline-Report-14317.html

Thrombosis Therapy Area Pipeline Report – Aarkstore Enterprise

Thrombosis Therapy Area Pipeline Report contains detailed information on the thrombosis drug pipeline. This report provides insight into the pipeline status of thrombosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.
 
For more information, visit us at:
http://www.aarkstore.com/reports/Thrombosis-Therapy-Area-Pipeline-Report-14311.html

Stroke_Cardiovascular and Circulatory System Therapy Area Pipeline Report – Aarkstore Enterprise

Stroke_Cardiovascular and Circulatory System Therapy Area Pipeline Report contains detailed information on the stroke – cardiovascular and circulatory system drug pipeline. This report provides insight into the pipeline status of stroke – cardiovascular and circulatory system drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.

For more information, visit us at:
http://www.aarkstore.com/reports/Stroke_Cardiovascular-and-Circulatory-System-Therapy-Area-Pipeline-Report-14309.html

Restenosis Therapy Area Pipeline Report – Aarkstore Enterprise

Restenosis Therapy Area Pipeline Report contains detailed information on the restenosis drug pipeline. This report provides insight into the pipeline status of restenosis drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.
 
For more information, visit us at:
http://www.aarkstore.com/reports/Restenosis-Therapy-Area-Pipeline-Report-14307.html

Peripheral Vascular Disease Therapy Area Pipeline Report – Aarkstore Enterprise

Peripheral Vascular Disease Therapy Area Pipeline Report contains detailed information on the peripheral vascular disease drug pipeline. This report provides insight into the pipeline status of peripheral vascular disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

• Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
• Keep track of your competitors and partners by better understanding their product pipeline.
• Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
• Maintain a critical competitive advantage.
 
For more information, visit us at:
http://www.aarkstore.com/reports/Peripheral-Vascular-Disease-Therapy-Area-Pipeline-Report-14306.html